This study evaluates the feasibility and accuracy of an AI-powered mobile platform (NuvanaDx) for early detection of skin cancer, including melanoma, using smartphone-based imaging. The platform is designed to improve access to early diagnosis, reduce waiting times, and support triage into appropriate care pathways.
The study will collect retrospective and prospective anonymized skin lesion images and metadata to validate the AI algorithm against dermatology-confirmed diagnoses. The aim is to determine sensitivity, specificity, and predictive value of the AI tool across diverse populations and skin tones. The study will also assess user experience, accessibility, and integration into clinical care pathways.
Study Type
OBSERVATIONAL
Enrollment
100
Smartphone-based AI skin lesion analysis (NuvanaDx platform).
Nuvana Healthcare Ltd
London, United Kingdom
RECRUITINGDiagnostic Accuracy of AI tool compared with dermatologist-confirmed diagnosis
Diagnostic Accuracy of AI tool compared with dermatologist-confirmed diagnosis Time Frame: Up to 12 months Measure: Sensitivity, specificity, and predictive values
Time frame: Time Frame: Up to 12 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.